Katgi, NuranCimen, PinarAkyol, MuratGursoy, PinarAguloglu, Nursin2024-03-092024-03-0920232979-9139https://doi.org/10.5152/ThoracResPract.2023.22200https://hdl.handle.net/20.500.14034/1502OBJECTIVE: Alectinib has a much better central nervous system transmission than crizotinib in patients diagnosed with anaplastic lym-phoma kinase mutation-positive nonsmall cell lung carcinoma. We aimed to investigate alectinib's efficacy in the treatment and its place in the first-line treatment and report our real-life data. MATERIAL AND METHODS: The data of 38 patients who were diagnosed with anaplastic lymphoma kinase-positive nonsmall cell lung carcinoma in our clinic between 2016 and 2021, who did not receive any treatment before were retrospectively analyzed. RESULTS: Of the 19 patients who received alectinib, 14 had multiple, and 6 had pretreatment brain metastases. No newly emerging brain metastases were detected during the treatment period. The progression-free survival of patients was 23.5 & PLUSMN; 4.2 months, and overall survival was 24.6 & PLUSMN; 4.1 months. Progression was observed in 10 (52.6%) patients. Of the 19 patients who received crizotinib, 7 had multiple metastases, and brain metastases were detected in 1 patient before treatment and 6 patients during the treatment period. Progression-free survival of crizotinib patients was 17.1 & PLUSMN; 4.8 months and their overall survival was 26.5 & PLUSMN; 6.1 months. Progression was observed in 17 (89.5%) patients. The second line of alectinib could be given to 8 of these patients. Overall survival after second-line treatment of alectinib was 18.2 & PLUSMN; 7.0 months. Overall survival of the patients who could not receive second-line treatment of alectinib was 4.0 & PLUSMN; 2.0 months. CONCLUSION: The progression rate was lower in alectinib than the crizotinib patients, although there were more patients with multiple metastases and brain metastases in the alectinib arm.eninfo:eu-repo/semantics/openAccessNonsmall Cell Lung Carcinoma; Anaplastic Lymphomakinase Mutation; Alectinib; Crizotinib; Brain MetastasisArticle10.5152/ThoracResPract.2023.22200244180+N/AWOS:0010486211000022-s2.0-8516594666437485706N/A